The EpiVax Immunogenicity scale shows the impact of T cell epitope content on overall immunogenicity. In the case of standard monoclonals, this “potential” is modified by the presence of Treg epitopes known as Tregitopes. If Tregs are not functioning, we surmise that the Treg epitopes (Tregitopes) do not immune modulate and they will be seen as T effector epitopes -thus all of the epitopes including Treg epitopes could drive ADA.
Recent Posts
- Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development
- Tregitopes by Another Name?
- Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop
- Change is Good! In with the New… EpiVax 2.0
- In Silico Immunogenicity Assessment of Therapeutic Peptides